Download PDF
Thromb Haemost 1970; 24(03/04): 345-351
DOI: 10.1055/s-0038-1654243
Originalarbeiten – Original Articles – Travaux Originaux
Schattauer GmbH

Blood Coagulation

Role of Hageman Protein (F-XII) and Autoprothrombin II (F-IX?) in the Activation of Autoprothrombin III (F-X)[*]
Walter H. Seegers
1   Department of Physiology and Pharmacology, Wayne State University, School of Medicine, Detroit, Michigan, U.S.A
,
Gary L. Grammens
1   Department of Physiology and Pharmacology, Wayne State University, School of Medicine, Detroit, Michigan, U.S.A
,
Lowell E. McCoy
1   Department of Physiology and Pharmacology, Wayne State University, School of Medicine, Detroit, Michigan, U.S.A
› Author Affiliations
Further Information

Publication History

Publication Date:
24 July 2018 (online)

Also available at
    Permissions and Reprints

Summary

Preparations of platelet factor 3 accelerated the conversion of purified autoprothrombin III (F-X) to autoprothrombin C (F-X?). The reaction was slow and the yields were low. Purified Hageman factor or purified autoprothrombin II (F-IX?) functioned as platelet cofactors. Each increased the yield of autoprothrombin C from purified autoprothrombin III above that obtained with platelet factor 3 alone. Hageman protein thus has a role in the direct acceleration of the first basic reaction in blood coagulation. Purified prothrombin was made refractory to the two-stage analytical reagents with Hageman factor.

* This work was supported by a research grant HE-03424-13 from the National Heart Institute, National Institutes of Health, U.S. Public Health Service. We wish to thank Eberhard F. Mammen for helpful suggestions and discussions.


 

  • References

  • 1 Ratnoff O. D, Colopy J. E. A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma. J. clin. Invest 34: 602 1955;
    CrossrefPubMedSearch in Google Scholar
  • 2 Ratnoff O. D, Margolius A. T. Hageman trait : Asymptomatic disorder of blood coagulation. Trans. Ass. Amer. Phycns 68: 149 1955;
    PubMedSearch in Google Scholar
  • 3 Didisheim P. Purification of Hageman factor. Fed. Proc 20: 61 1961;
    PubMedSearch in Google Scholar
  • 4 Haanen C, Hommes F, Berroad H, Morselt G. A case of Hageman factor deficiency and a method to purify the factor. Thrombos. Diathes. haemorrh. (Stuttg.) 05: 201 1960;
    PubMedSearch in Google Scholar
  • 5 Ratnoff O. D, Davie E. W. The purification of activated Hageman factor (activated factor XII). Biochemistry 01: 967 1962;
    CrossrefPubMedSearch in Google Scholar
  • 6 Schoenmakers J. G. G, Kurstjens R. M, Haanen G, Zilliken F. Purification of activated Hageman factor. Thrombos. Diathes. haemorrh. (Stuttg.) 09: 546 1963;
    PubMedSearch in Google Scholar
  • 7 Schoenmakers J. G. G, Matzke R, Haanen C, Zilliken F. Hageman factor, a novel sialoglycoprotein with esterase activity. Biochim. biophys. Acta (Amst.) 101: 166 1965;
    PubMedSearch in Google Scholar
  • 8 Speer R. J, Ridgeway H, Hill M. J. Activated human Hageman factor (XII). Thrombos. Diathes. haemorrh. (Stuttg.) 14: 1 1965;
    PubMedSearch in Google Scholar
  • 9 Grammens G. L. The isolation and properties of bovine Hageman factor (factor XII). M.S. Thesis, Wayne State Univ. Detroit; Michigan: 1966
    Search in Google Scholar
  • 10 Davie E. W, Ratnoff O. D. Waterfall sequence for intrinsic blood clotting. Science 145: 1310 1964;
    CrossrefPubMedSearch in Google Scholar
  • 11 Macfarlane R. G. An enzyme cascade in blood clotting mechanism, and its function as a biochemical amplifier. Nature (Lond.) 202: 498 1964;
    CrossrefPubMedSearch in Google Scholar
  • 12 Esnouf M. P. Biochemical aspects of blood coagulation. Proc. Roy. Soc. Ser. B 173: 269 1969;
    CrossrefPubMedSearch in Google Scholar
  • 13 Mammen E. F, Grammens G. L. The purification and some properties of bovine Hageman factor. Thrombos. Diathes. haemorrh. (Stuttg.) 18: 306 1967;
    PubMedSearch in Google Scholar
  • 14 Glueck H. I, Roehll Jr. W. Myocardial infarction in a patient with a Hageman (factor XII) defect. Ann. intern. Med 64: 390 1966;
    CrossrefPubMedSearch in Google Scholar
  • 15 Hoak J. C, Swanson L. W, Warner E. D, Connor W. E. Myocardial infarction associated with severe factor XII deficiency. Lancet II: 884 1966;
    PubMedSearch in Google Scholar
  • 16 Ratnoff O. D, Busse J. R, Sheon R. P. The demise of John Hageman. New Engl. J. Med 279: 760 1968;
    CrossrefPubMedSearch in Google Scholar
  • 17 Macfarlane R. G. The blood clotting mechanism. Proc. Roy. Soc. Ser. B 173: 261 1969;
    CrossrefPubMedSearch in Google Scholar
  • 18 Seegers W. H. The purification of prothrombin. Rec. Chem. Progr 13: 143 1952;
    PubMedSearch in Google Scholar
  • 19 Mammen E. F, Thomas W. R, Seegers W. H. Activation of purified prothrombin to autoprothrombin I or autoprothrombin II (platelet cofactor II) or autoprothrombin II-A. Thrombos. Diathes. haemorrh. (Stuttg.) 05: 218 1960;
    PubMedSearch in Google Scholar
  • 20 Ware A. G, Seegers W. H. Two-stage procedure for the quantitative determination of prothrombin concentration. Amer. J. clin. Path 19: 471 1949;
    PubMedSearch in Google Scholar
  • 21 Seegers W. H, Smith H. P. Factors which influence the activity of purified thrombin. Amer. J. Physiol 137: 348 1942;
    PubMedSearch in Google Scholar
  • 22 Marciniak E, Seegers W. H. Autoprothrombin C: A second enzyme from prothrombin. Canad. J. Biochem. Physiol 40: 597 1962;
    PubMedSearch in Google Scholar
  • 23 Alkjaersig N, Abe T, Seegers W. H. Purification and quantitative determination of platelet factor 3. Amer. J. Physiol 181: 304 1955;
    PubMedSearch in Google Scholar
  • 24 Seegers W. H, Marciniak E, Kipfer R. K, Yasunaga K. Isolation and some properties of prethrombin and autoprothrombin III. Arch. Biochem 121: 372 1967;
    CrossrefPubMedSearch in Google Scholar
  • 25 Reno R. S, Seegers W. H. Two-stage procedure for the quantitative determination of autoprothrombin III concentration and some applications. Thrombos. Diathes. haemorrh. (Stuttg.) 18: 198 1967;
    PubMedSearch in Google Scholar
  • 26 Seegers W. H. Prothrombin. Harvard Univ. Press. Cambridge, Mass. USA: 1962
    Search in Google Scholar
  • 27 Connor W. E, Hoak J. C, Warner E. D. Plasma free fatty acids, hypercoagulability, and thrombosis. In: Sherry S, Brinkhous K. M, Genton E, Stengle J. M. Thrombosis. 355 Nat. Acad. Sci. 1969
    Search in Google Scholar
  • 28 Caldwell M. J, von Kaulla K. N, von Kaulla E, Seegers W. H. Procoagulant material from human urine in prothrombin activation. Thrombos. Diathes. haemorrh. (Stuttg.) 09: 53 1963;
    PubMedSearch in Google Scholar
  • 29 Seegers W. H, McCoy L, Marciniak E, Murano G. Theory of blood coagulation: Applications in disseminated intravascular coagulation. Thrombos. Diathes. haemorrh (Stuttg.) Suppl. 36: 239 1969;
    PubMedSearch in Google Scholar
  • 30 Triantaphyllopoulos D. C, Triantaphyllopoulos E. Antihemophilic factor-like activity of lysed fibrinogen. Life Sci 06: 601 1967;
    CrossrefPubMedSearch in Google Scholar